Thanks for emailing that article!
Key to helping prevent irrevocable vision loss from glaucoma is early detection combined with effective treatment. But to date, mechanisms to evaluate the progression of glaucoma have been limited.
Now investigators with the Catalyst for a Cure (CFC) Biomarker Initiative are on the verge of upending this barrier through the identification of new biological markers for glaucoma. Biomarkers can provide physicians with better tools to diagnose and manage glaucoma before vision is lost, as well as accelerate the pace of discovery toward better treatments and ultimately a cure for glaucoma.
Setting the agenda for glaucoma research, Glaucoma Research Foundation established the CFC Biomarker Initiative in 2012. The consortium builds on the success of the first CFC initiative and harnesses the abilities of four investigators — Alfredo Dubra, PhD, Jeffrey L. Goldberg, MD, PhD, Andrew G. Huberman, PhD, and Vivek Srinivasan, PhD — who were tasked with finding biomarkers for glaucoma.
The four researchers, working in laboratories at prestigious academic centers, bring expertise in disciplines ranging from biomedical imaging, physics, retinal cell biology, and neurobiology to clinical ophthalmology. “The principle is team science,” explains Dr. Goldberg, “with the intent of discovering fundamental biology, implementing it in innovative engineering, and pushing it from the laboratory into the clinic.”
Thanks to the CFC Biomarker Initiative, identification of molecular biomarkers for glaucoma has greatly accelerated. The CFC investigators have made extraordinary progress in speeding the progress of investigation, and they are now at a critical tipping point.
Motivated by the hypothesis that structural and/or metabolic changes in the retina will allow eye doctors to detect and monitor glaucoma and evaluate treatment efficacy, the researchers focused their attention on the retinal ganglion cells (RGCs). The health and evaluation of the RGCs are fundamental to glaucoma, because as RGCs degenerate and die, vision is lost.
Through their investigations, the researchers identified which types of RGCs are injured or die first in glaucoma. Then the team developed state-of-the-art imaging equipment to noninvasively measure structural and biological changes in the RGCs.
With the aid of the diagnostic tools they created, the researchers have identified biomarkers that may be among the earliest to show changes in glaucoma.
The CFC team now has eight potential new biomarkers and they are focusing on three of the most promising:
Mitochondria that are damaged or not working correctly can result in the damage and eventual death of RGCs. By observing and measuring changes to the mitochondria, it may be possible to help ensure the health of the RGCs before vision is lost.
Changes in oxygen saturation can be harmful to the eye and may play a role in glaucoma. Specialized equipment developed by the team can be used in the clinic to measure changes in oxygen saturation to diagnose and monitor glaucoma more effectively.
Being able to view early changes in the retina’s vascular, nerve fiber, and ganglion cell components could allow doctors to step in before the nerve cells are damaged.
Based on the investigators' findings, the implications for treatment are profound. In addition to allowing doctors to intervene before the nerve cells are damaged, biomarkers can lead to faster drug discovery by quickly demonstrating efficacy, and they hold promise of helping eye doctors provide personalized treatment specific to each patient’s diagnosis.
Functional tests for these new biomarkers have been validated in models of glaucoma and are now being tested in patients. “The researchers’ ability to bridge from laboratory studies to human studies, and now take that into the clinic, is what we set out to do six years ago,” says Dr. Huberman.
The consortium is now focused on a bold new goal: a pathway toward a therapeutic strategy for restoring lost vision in glaucoma patients.
“Two clinical trials are underway for vision restoration,” says Dr. Huberman. “These trials would not be possible without the identification of the new biomarkers and the new imaging equipment that the team has built.”
The impact of the consortium’s work cannot be overstated: the CFC Biomarkers Initiative is on the verge of changing the future of how glaucoma is diagnosed and treated. It has the real potential to transform clinical care, and, most importantly, to change lives.
Last reviewed on October 29, 2017
This article appeared in the May 2017 issue of Gleams.Subscribe